

## **ASX ANNOUNCEMENT**

## ASX: VXL & VXLO

25 July 2014

## **EXERCISE OF OPTIONS**

Valence Industries Limited (ASX: VXL & VXLO) ("Valence" or "the Company") advises that shareholders have exercised listed options (ASX: VXLO) issued by the Company. All listed options have an exercise price of 25 cents per share and expiry of 31 July 2016.

Valence advises that it has issued listed shares upon the exercise of options, and provides the following information in relation to the issue as required under the listing rules:

Number of securities	250,000
Class and terms	Fully paid ordinary shares
Issue price	25 cents per share
Purpose of the issue	Exercise of options by shareholders
Will the entity seek shareholder	No. The shares are issued under listing rule 7.2, exception
approval	4 and shareholder approval is not required
Class of security holder	Not applicable

An updated Appendix 3B seeking quotation of the shares is attached to this announcement.

For further information, please contact:

Jaroslaw (Jarek) Kopias CFO & Company Secretary Valence Industries info@valenceindustries.com +61 8 8418 8564



## **VALENCE INDUSTRIES**

#### **About Valence Industries & Graphite Manufacturing**

Valence Industries (ASX:VXL & VXLO) is the owner and operator of the only graphite mining and manufacturing facilities in Australia located at Uley in South Australia near the major regional centre of Port Lincoln. In April 2014 and just four months after listing on the ASX, Valence Industries achieved the first sales of graphite by an Australian company in more than 20 years.

The Company is bringing its existing plant and substantial infrastructure into production in Phase I with a focus on global markets across multiple graphite product ranges. Graphite production will commence in the third Quarter of 2014, with plans for expanded mining and graphite manufacturing in Phase II increasing through 2015.

Located only 23 kilometres from Port Lincoln, the regional centre for the Lower Eyre Peninsula in South Australia, Valence Industries' Uley Graphite project is recognised as a significant area of graphite mineralisation, and one of the largest coarse flake graphite deposits in the world. The deposit contains disseminated, high-grade flake graphite and the mineralisation is near surface, with the final manufactured graphite products recognised and purchased by many customers for its high quality.

The company holds two existing Mining Leases and two associated Retention Leases, along with an extensive Exploration Licence, for the conduct of its operations.

Valence Industries is in the fortunate position of owning the land on which its current and proposed expanded operations are conducted along with the extensive existing infrastructure.


#### Manufacturing A New Carbon Future & Advanced Graphene Program

The Company operates as an industrial manufacturer of high-grade flake graphite products for distribution and sale to global markets. Valence Industries owns established processing facilities and infrastructure to manufacture a wide range of graphite product lines for multiple applications and multiple industries.

The Company produces and sells its graphite products from its Uley Graphite facilities in regional South Australia for delivery to diversified markets for graphite in the Asia Pacific, Europe and North America. As a vertically integrated manufacturer of specialist graphite product ranges Valence Industries' branded products are designed to meet current and future customer demand.

The Company is also pursuing research into advanced fields and applications for graphite. That program includes the relationship with the University of Adelaide for the establishment of a dedicated Graphene Research Centre in Adelaide. Graphene is one of the most significant steps forward in the world of advanced materials with the potential for transformative and disruptive technologies and the leading research in this area from the University of Adelaide on natural flake graphite has originated from work on the Company's Uley Graphite. The Graphene Research Centre program will see the development and commercialisation of processes and products for the application of graphene.







Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Valence Industries Limited

ABN

41 008 101 979

We (the entity) give ASX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)



<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?


If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

6a Is the entity an <sup>+</sup>eligible entity ] that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- 6c Number of \*securities issued without security holder approval under rule 7.1



<sup>+</sup> See chapter 19 for defined terms.

6d Number of \*securities issued with security holder approval under rule 7.1A

6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

- 6f Number of +securities issued under an exception in rule 7.2
- 6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.
- 6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

#### 7 <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	+Class
135,598,708	Ordinary shares
52,340,786	Listed Options exercisable at 25 cents on or before 31 July 2016.

7.1 – 25,262,302 7.1A – Not applicable

<sup>+</sup> See chapter 19 for defined terms.

9

	Number	+Class
Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	32,816,642	Ordinary shares escrowed to 6 January 2016.
	16,250,000	Listed Options exercisable at 25 cents on or before 31 July 2016 escrowed to 6 January 2016.
	3,500,000	Unlisted Options exercisable at 25 cents on or before 31 July 2016 escrowed to 6 January 2016 - vested.
	2,050,000	Unlisted Options exercisable at 25 cents on or before 31 July 2016 escrowed to 6 January 2016 – unvested and subject to performance criteria.
	1,375,000	Unlisted performance rights escrowed to 6 January 2016 and subject to performance criteria.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) Same as for all other securities

<sup>+</sup> See chapter 19 for defined terms.

## Part 2 - Pro rata issue

Is security holder 11 approval required? Is the issue renounceable or non-12 renounceable? Ratio in which the \*securities 13 will be offered <sup>+</sup>Class of <sup>+</sup>securities to which the 14 offer relates <sup>+</sup>Record date to determine 15 entitlements different 16 Will holdings on registers (or subregisters) be aggregated for calculating entitlements? Policy for deciding entitlements 17 in relation to fractions 18 Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. Closing date for receipt of 19 acceptances or renunciations Names of any underwriters 20 Amount of any underwriting fee 21 or commission Names of any brokers to the 22 issue Fee or commission payable to the 23 broker to the issue

#### Appendix 3B New issue announcement

Amount of any handling fee 24 payable to brokers who lodge acceptances or renunciations on behalf of security holders 25 If the issue is contingent on security holders' approval, the date of the meeting Date entitlement and acceptance 26 form and offer documents will be sent to persons entitled If the entity has issued options, 27 and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) Date rights trading will end (if 29 applicable) How do security holders sell 30 their entitlements in full through a broker? How do security holders sell part 31 of their entitlements through a broker and accept for the balance? How do security holders dispose 32 of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Issue date



## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of +securities 34

(tick one)

(a)

(b)

35

37

	<sup>+</sup> Securities described in Part
--	---

All other \*securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- If the *+*securities are *+*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders
- 36 If the +securities are +equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

A copy of any trust deed for the additional +securities

<sup>+</sup> See chapter 19 for defined terms.

Entiti	es that have ticked box 34(b)		
38	Number of <sup>+</sup> securities for which <sup>+</sup> quotation is sought	250,000	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	Fully paid ordinary sha	ares
40	<ul> <li>Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?</li> <li>If the additional *securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul>	Yes	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)	Exercise of listed optic	ons by shareholders
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number 135,598,708 52,340,786	+Class Ordinary shares Listed Options exercisable at 25 cents on or before 31

### Entities that have ticked box 34(b)

July 2016.

#### **Quotation agreement**

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Company secretary

Date: 25 July 2014

Print name:

Jaroslaw (Jarek) Kopias

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	115,547,375 (on admission to ASX prior to placement under prospectus)	
<b>Add</b> the following:	22.672.677 (rights issue for admission to	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> <li>Note: <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate</li> </ul> </li> </ul>	<ul> <li>33,673,677 (rights issue for admission to ASX) – 24 December 2013</li> <li>687,500 (issue upon exercise of performance rights on issue prior to admission to ASX) – 20 January 2014</li> <li>17,024,453 (rights issue shortfall) – 4 February 2014</li> <li>1,482,345 (exercise of listed options) – between 16 April 2014 and 25 July 2014</li> </ul>	
line items Subtract the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period "A"	168,415,350	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	25,262,302

# Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil
Under an exception in rule 7.2	
Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	25,262,302
Note: number must be same as shown in	

"A" x 0.15	25,262,302
Note: number must be same as shown in Step 2	
Subtract "C"	Nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	25,262,302
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A"	Not applicable
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
<i>Multiply</i> "A" by 0.10	
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	

<sup>+</sup> See chapter 19 for defined terms.

"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.